Corvus Pharmaceuticals Inc. (NASDAQ: CRVS)
$4.5300
-0.4600 ( -8.49% ) 612.3K
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Market Data
Open
$4.5300
Previous close
$4.9900
Volume
612.3K
Market cap
$302.65M
Day range
$4.5300 - $5.0070
52 week range
$1.3000 - $10.0000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | May 07, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |
8-k | 8K-related | 20 | May 06, 2024 |
8-k | 8K-related | 16 | May 06, 2024 |
8-k | 8K-related | 14 | May 01, 2024 |
def | Proxies and info statements | 6 | Apr 26, 2024 |
10-k | Annual reports | 90 | Mar 19, 2024 |
8-k | 8K-related | 17 | Mar 19, 2024 |
4 | Insider transactions | 1 | Mar 01, 2024 |
3 | Insider transactions | 2 | Feb 08, 2024 |